The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed at $454.67 in the last session, down -1.29% from day before closing price of $460.59. In other words, the price has decreased by -$1.29 from its previous closing price. On the day, 1.35 million shares were traded. VRTX stock price reached its highest trading level at $462.31 during the session, while it also had its lowest trading level at $452.91.
Ratios:
We take a closer look at VRTX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.57. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Wolfe Research Upgraded its Peer Perform to Outperform on January 06, 2026, while the target price for the stock was maintained at $548.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 07 ’26 when Tatsis Ourania sold 4,500 shares for $474.99 per share. The transaction valued at 2,137,455 led to the insider holds 42,293 shares of the business.
WAGNER CHARLES F JR sold 9,532 shares of VRTX for $4,394,252 on Jan 06 ’26. The EVP, CO & FO now owns 37,725 shares after completing the transaction at $461.00 per share. On Jan 07 ’26, another insider, Tatsis Ourania, who serves as the Officer of the company, bought 4,500 shares for $474.99 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 116573143040 and an Enterprise Value of 110906138624. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 32.04, and their Forward P/E ratio for the next fiscal year is 22.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.83 while its Price-to-Book (P/B) ratio in mrq is 6.67. Its current Enterprise Value per Revenue stands at 9.46 whereas that against EBITDA is 23.538.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.31, which has changed by 0.08563149 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.68, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is 2.56%, while the 200-Day Moving Average is calculated to be 3.83%.
Shares Statistics:
According to the various share statistics, VRTX traded on average about 1.37M shares per day over the past 3-months and 1273150 shares per day over the past 10 days. A total of 253.95M shares are outstanding, with a floating share count of 253.00M. Insiders hold about 0.28% of the company’s shares, while institutions hold 94.56% stake in the company. Shares short for VRTX as of 1767139200 were 5022282 with a Short Ratio of 3.68, compared to 1764288000 on 4455217. Therefore, it implies a Short% of Shares Outstanding of 5022282 and a Short% of Float of 2.2399999999999998.
Earnings Estimates
Its stock is currently analyzed by 21.0 different market analysts. The consensus estimate for the next quarter is $4.82, with high estimates of $5.43 and low estimates of $4.29.
Analysts are recommending an EPS of between $19.1 and $17.2 for the fiscal current year, implying an average EPS of $18.43. EPS for the following year is $20.18, with 24.0 analysts recommending between $22.31 and $18.15.
Revenue Estimates
According to 26 analysts,. The current quarter’s revenue is expected to be $3.18B. It ranges from a high estimate of $3.35B to a low estimate of $3.1B. As of. The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.91BFor the next quarter, 26 analysts are estimating revenue of $3.14B. There is a high estimate of $3.26B for the next quarter, whereas the lowest estimate is $2.99B.
A total of 29 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.22B, while the lowest revenue estimate was $11.87B, resulting in an average revenue estimate of $11.98B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.01B in the next fiscal year. The high estimate is $13.54B and the low estimate is $12.05B.
